搜尋結果
2022年4月19日 · A study by the University of Hong Kong has for the first time compared the effectiveness of China’s Sinovac vaccine with the mRNA vaccine developed by BioNTech against the Omicron variant of...
2021年2月19日 · 早前香港醫院藥劑師學會就比較了科興 (Sinovac)疫苗、復星 (Fosun) / BioNTech及阿斯利康 (AstraZeneca)於副作用、產地、有效率等方面的分別，即睇三大供港疫苗的比較分析詳情。 科興 (Sinovac)疫苗. 疫苗生產地為中國北京，種類屬滅活疫苗，劑型為預充式注射器，每支注射器可提供一個劑量。 臨床研究中常見副作用. 點擊圖片放大. 第一針及第二針發燒率. 18至59歲：第一針：2.1%；第二針：1.4% 效能. 50.66%-62.3%。 調配方法. 不用稀釋或解凍. 運送方法. 運送過程需維持 2°C 至 8 °C. 接種中心地址. 點擊圖片放大. 復星 (Fosun) / BioNTech.
2021年6月24日 · Updated: January 3rd, 2021. Written by Dr David Owens. Answer: Of the two available vaccines in Hong Kong BioNTech is the most effective. Both the vaccines available in Hong Kong are very good at preventing death and serious illness against the original SARS-COV-2 virus.
2021年7月29日 · Against the original virus BioNTech was 95% effective compared to 50.7% for Sinovac. BioNTech drops to 88% against Delta. Recent studies suggest that Sinovac is significantly less effective against Delta and has no neutralizing immunity against Omicron
- Who Can Be Vaccinated?
- Should Pregnant and Breastfeeding Women Be Vaccinated?
- Who Is The Vaccine Not Recommended for?
- Is It Safe?
- How Efficacious Is The Vaccine?
- What Is The Recommended Dosage?
- Is A Booster Dose Recommended For This Vaccine?
- Can This Vaccine Be ‘Mixed and Matched’ with Other Vaccines?
- Does It Prevent Infection and Transmission?
- Does It Work Against New Variants of Sars-Cov-2 Virus?
The vaccine is safe and effective for all individuals aged 18 and above. In line with the WHO Prioritization Roadmap and the WHO Values Framework, older adults, health workers and immunocompromised persons should be prioritised. The Sinovac vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to delay vacci...
The available data on the Sinovac-CoronaVac (COVID-19) vaccine in pregnant women are insufficient to assess either vaccine efficacy or possible vaccine-associated risks in pregnancy. However, this vaccine is an inactivated vaccine with an adjuvant that is commonly used in many other vaccines with a well-documented safety profile, such as Hepatitis ...
The vaccine is not recommended for persons younger than 18 years of age, pending the results of further studied in that age group. Individuals with a history of anaphylaxis to any component of the vaccine should not take it. Persons with acute PCR-confirmed COVID-19 should not be vaccinated until after they have recovered from acute illness and the...
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above. Safety data is currently limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared...
A large phase 3 trial in Brazil showed that two doses, administered at an interval of 14 days, had an efficacy of 51% against symptomatic SARS-CoV-2 infection, 100% against severe COVID-19, and 100% against hospitalization starting 14 days after receiving the second dose.
SAGE recommends the use of Sinovac-CoronaVac vaccine as 2 doses (0.5 ml) given intramuscularly. SAGE recommends that a third, additional dose of the Sinovac vaccine be offered to persons aged 60 and above as part of an extension of the primary series. Current data does not indicate the need for an additional dose in persons under 60 years of age. S...
A booster dose may be considered 4 – 6 months after completion of the primary vaccination series, starting with the higher priority-use groups, in accordance with the WHO Prioritization Roadmap. The benefits of booster vaccination are recognized following increasing evidence of waning vaccine effectiveness against mild and asymptomatic SARS-CoV-2 i...
SAGE accepts two heterologous doses of WHO EUL COVID-19 vaccines as a complete primary series. To ensure equivalent or favourable immunogenicity or vaccine effectiveness either of the WHO EUL COVID-19 mRNA vaccines (Pfizer or Moderna) or the WHO EUL COVID-19 vectored vaccines (AstraZeneca Vaxzevria/COVISHIELD or Janssen) can be used as a second dos...
There is currently no substantive data available related to the impact of COVID-19 vaccine Sinovac-CoronaVac on transmission of SARS-CoV-2, the virus that causes COVID-19 disease. In the meantime, WHO reminds of the need to stay the course and continue practicing public health and social measures that should be used as a comprehensive approach to p...
In an observational study, the estimated effectiveness of Sinovac-CoronaVac in health workers in Manaus, Brazil, where P.1 accounted for 75% of SARS-CoV-2 samples was 49.6% against symptomatic infection (4). Effectiveness has also been shown in an observational study in Sao Paulo in the presence of P1 circulation (83% of samples). There are still i...
2022年4月1日 · 截止目前，中國沒有批准任何mRNA疫苗，主要使用國產滅活疫苗國藥（Sinopharm）和科興（Sinovac）。 據路透社報道，中國唯一進入三期臨牀試驗的mRNA候選疫苗是ARCoV，由中國軍事科學院、蘇州艾博生物科技有限公司、雲南沃森生物技術股份有限公司聯合研發。...
2021年2月25日 · 國產科興疫苗首批100萬劑疫苗已於日前運抵本港，而首批德國生產的BioNTech疫苗「復必泰」疫苗原定今（25日）抵港，惟政府證實因出口程序未完成，未能預期運到香港。 新冠疫苗接種計劃將於明日起展開。 中大香港亞太研究所城市與區域發展研究中心就疫苗在同步接種或延遲接種的情況下，評估比較本港預購3款疫苗的平均保護率，即分別有科興疫苗、阿斯利康/牛津疫苗、BioNTech/復星「復必泰」疫苗。 閱讀全文. 27065次閱讀. 新冠疫苗 新冠病毒抗體測試. 有研究就疫苗在同步接種或延遲接種的情況下，評估比較本港預購3款疫苗的平均保護率，即分別有科興疫苗、阿斯利康/牛津疫苗、BioNTech/復星「復必泰」疫苗。
